Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.
暂无分享，去创建一个
R. Rosell | N. Reguart | A. Cardona | C. Rolfo | O. Arrieta | Z. Zatarain-Barrón | A. Ruíz-Patiño | H. Carranza | C. Vargas | J. Otero | L. Rojas | L. Corrales | Claudio Martín | M. Cuello | L. Pino | B. Wills | C. Martin